ArticleBMC neurology2015
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
Article in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Association between gout, hyperuricemia, and Parkinson's disease: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2022Pooled it
- Inflammatory rheumatic diseases and the risk of Parkinson's disease: A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.Clinical and experimental nephrology · 2020Trial
- Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and therapeutic targets.Frontiers in cell and developmental biology · 2026Review
- An assessment of an antioxidative status in patients with multiple sclerosis using standard biochemical analyses.Journal of medical biochemistry · 2025Article
- Association between gout, hyperuricaemia and Parkinson's disease risk: a cohort study in western Sweden (2001-2017).Rheumatology advances in practice · 2025Article
- Impact of gout on colorectal cancer and its survival: a two-sample Mendelian randomization study.Discover oncology · 2024Article
- Biological constraint, evolutionary spandrels and antagonistic pleiotropy.Ageing research reviews · 2024Review
- Update: Protective and risk factors for Parkinson disease.Parkinsonism & related disorders · 2024Review
- Effect of Whole-Body Cryotherapy on Oxidant-Antioxidant Imbalance in Women with Multiple Sclerosis.Journal of clinical medicine · 2023Article
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
- Longitudinal follow-up study of the association with gout and Alzheimer's disease and Parkinson's disease in Korea.Scientific reports · 2023Article
- Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries.PloS one · 2023Article
- Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study.Journal of Parkinson's disease · 2023Article
- Dose-response meta-analysis on urate, gout, and the risk for Parkinson's disease.NPJ Parkinson's disease · 2022Review
- Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using a Systematic Screening Approach in a Nationwide Nested Case-Control Study.Clinical epidemiology · 2022Article
- Risk of Parkinson's disease following gout: a population-based retrospective cohort study in Taiwan.BMC neurology · 2020Article
- Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data.BMC neurology · 2019Article
- Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease.Annals of neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundUric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective effect against the risk of developing some neurological diseases. We aimed to investigate this hypothesis in a large database of hospital admissions in England.
methodsWe analysed a database of linked statistical records of hospital admissions and death registrations in England (1999-2012). A cohort of people with gout was constructed and followed for development of multiple sclerosis (MS), Parkinson's disease (PD) or motor neuron disease (MND). Then, conversely, cohorts of all people in the database with MS, PD or MND were constructed and followed for subsequent gout. Rate ratios (RRs) were determined, comparing these cohorts with people in a reference cohort.
resultsIn the gout cohort, we observed a modest elevation of the overall risk of subsequent MS, PD and MND (respectively, RR = 1.27 (95% confidence interval 1.03-1.55), 1.11 (1.05-1.17) and 1.28 (1.11-1.48) which was largely attributable to an increased risk observed in the early years after hospitalisation for gout. The increased risk of neurological disease did not remain after 5 years. In the cohorts of people with MS or PD, there was a significantly reduced risk of subsequent gout admission (RR = 0.79 (0.69-0.89) and 0.83 (0.79-0.87), respectively). This inverse association was sustained over time. There was also a reduced risk of MND following gout which only emerged more than five years following initial gout admission (RR at 5+ years 0.35 (0.15-0.68)).
conclusionsThis study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND. Our observations do not support this hypothesis. However, when the order was reversed, and we retrospectively followed up patients with MS, PD and MND for a number of years, we found a statistically significant deficit of gout. This suggests that there is relationship between some aspects of these neurodegenerative diseases and metabolism of uric acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.